August 27, 2019 09:20 AM EDTUpdated 10:01 AM
Deals

GSK li­cens­es Ion­is' ex­per­i­men­tal hep B treat­ments in up to $262M deal

Natalie Grover

Reporter

GSK $GSK may have walked away from two of Io­n­is’ $IONS an­ti­sense drugs (in­clud­ing the now-ap­proved Tegse­di) in 2017 — but the British drug­mak­er held …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times